Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-24, Stock:NVS, The news for the past five days is as follows:
2019-06-17: NEWS1: J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study.NEWS2: J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study.NEWS3: Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz.NEWS4: Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz.NEWS5: J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study.NEWS6: Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz.
2019-06-18: NEWS1: Online pharmacy flags possible new impurity in blood pressure drug.NEWS2: Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status.NEWS3: Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status.NEWS4: Roche's Rozlytrek Gets Approval in Japan for Solid Tumors.NEWS5: Roche's Rozlytrek Gets Approval in Japan for Solid Tumors.NEWS6: Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status.NEWS7: Alcon Inc. -- Moody's assigns Baa2 ratings to Alcon Inc.'s unsecured debt facilities.NEWS8: Roche's Rozlytrek Gets Approval in Japan for Solid Tumors.
2019-06-19: NEWS1: NVS or NVO: Which Is the Better Value Stock Right Now?.NEWS2: NVS or NVO: Which Is the Better Value Stock Right Now?.NEWS3: NVS or NVO: Which Is the Better Value Stock Right Now?.
2019-06-20: NEWS1: 3 Drugs Under FDA Review With Blockbuster Potential.NEWS2: 3 Drugs Under FDA Review With Blockbuster Potential.NEWS3: From generic drugs to gummies: Boulder CBD company buys Novartis pharmaceutical plant in Broomfield for $18.8M.
2019-06-21: NEWS1: Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval.NEWS2: Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval.NEWS3: Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval.NEWS4: Oh, By the Way, This Clinical Trial Didn't Work.NEWS5: Oh, By the Way, This Clinical Trial Didn't Work.NEWS6: UPDATE 1-U.S. group says Novartis MS drug price out of line with benefit.NEWS7: U.S. group says Novartis MS drug price out of line with benefit.

Answer: Rise